Alnylam Pharmaceuticals (NASDAQ:ALNY) Posts Quarterly Earnings Results, Beats Expectations By $14.60 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping the consensus estimate of $1.66 by $14.60, FiscalAI reports. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the business posted $2.90 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• Q3 product revenue rose 52% year over year to approximately $1.3 billion, driven by AMVUTTRA and 59% growth in TTR revenue to $1.15 billion. Alnylam also ended the quarter with $3.6 billion in cash and marketable securities.
• Management expects 2026 TTR revenue at the low end of its $4.2 billion–$4.5 billion range, acknowledging that expanded commercial efforts have not yet translated into demand growth as quickly as anticipated. Potential fourth-quarter ordering volatility from the 340B rule and tighter UnitedHealth Medicare Advantage access may add pressure.
• Alnylam will expand the TRITON-CM study for nucresiran by 500 patients to approximately 2,250, primarily to account for potentially lower event rates as patients are diagnosed earlier and receive better background treatment. The company said the change is intended to improve statistical power and does not alter the expected ATTR cardiomyopathy launch timing of around 2030.
• Early brezosiran data in Huntington’s disease showed 60%–64% mean reductions in cerebrospinal-fluid mutant huntingtin, with reductions of up to 83% and no dose-dependent safety signals reported to date. Alnylam plans to advance the program toward a pivotal study in 2027, pending regulatory alignment.

Alnylam Pharmaceuticals Trading Down 25.1%

NASDAQ:ALNY opened at $174.00 on Friday. The firm’s fifty day moving average is $237.78 and its 200-day moving average is $287.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals has a 52 week low of $172.31 and a 52 week high of $479.79. The firm has a market cap of $23.28 billion, a P/E ratio of 32.34 and a beta of 0.28.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALNY. Citigroup reduced their target price on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Bank of America restated a “buy” rating and issued a $287.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. HC Wainwright reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday. Finally, Needham & Company LLC cut their target price on Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating on the stock in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $342.90.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of $1.46 billion, up approximately 17% year over year and ahead of the $1.43 billion consensus estimate. Adjusted earnings were $16.26 per share, substantially above expectations, although the result was boosted by a roughly $1.9 billion tax benefit. Alnylam Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Management maintained its fiscal 2026 net product-sales outlook and expects $4.2 billion to $4.5 billion in transthyretin (TTR) product sales, supporting continued growth for Amvuttra and the broader commercial business. Alnylam TTR Sales Outlook
• Positive Sentiment: The company reaffirmed confidence in nucresiran and expanded the Phase 3 TRITON-CM study to approximately 2,250 patients, potentially strengthening the evidence base for a future cardiomyopathy indication.
• Neutral Sentiment: Alnylam temporarily halted trading under a volatility-related LULD pause as investors absorbed the earnings release and conference-call commentary.
• Negative Sentiment: Investors reacted negatively to the decision to expand the nucresiran heart-failure trial while retaining an expected launch timeline around 2030. The larger study raises near-term costs and may delay profitability, despite management’s stated conviction in the program. Alnylam Nucresiran Trial Expansion
• Negative Sentiment: U.S. Amvuttra and Onpattro sales growth slowed, raising concern that the company’s core TTR franchise may be maturing and making future growth increasingly dependent on pipeline launches. Alnylam Sales Growth Slows
• Negative Sentiment: Stifel downgraded ALNY from Buy to Hold with a $225 price target, while Needham cut its target from $357 to $243 but retained a Buy rating. The target reductions highlight heightened valuation and execution concerns. Stifel Downgrades Alnylam

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.